Iron homeostasis is tightly regulated in the body. Hepcidin acts as the master regulator of iron by inhibiting intestinal iron absorption and macrophage iron release. Disorders of iron overload occur when hepcidin production is insufficient, such as in hereditary hemochromatosis. The most common type is HFE hemochromatosis caused by mutations of the HFE gene. Treatment involves regular phlebotomy to reduce iron levels. Family screening is important given the hereditary nature of the disease.
Iron is an essential mineral that is distributed throughout the body and is important for oxygen transport and cellular metabolism. Iron deficiency develops when requirements exceed supply and leads to iron deficient erythropoiesis and eventually iron deficiency anemia. It is one of the most common nutritional deficiencies worldwide, affecting toddlers, adolescent girls, pregnant women, and some minority groups. Treatment involves oral or parenteral iron supplementation depending on severity, with the goal of replenishing iron stores and repairing hemoglobin deficits.
Approach to a case of iron defciency anaemiaSachin Adukia
- Anaemia is defined as a reduction in haemoglobin, red blood cell count or haematocrit below normal levels. Iron-deficiency anaemia affects around 2 billion people worldwide including 20-40% of people in India.
- Iron-deficiency anaemia is classified based on the underlying cause such as reduced red blood cell production, increased red blood cell destruction, or loss of red blood cells.
- Diagnosis involves examination of symptoms, signs, and laboratory tests including a blood smear, iron studies, and bone marrow examination. Treatment involves oral or intravenous iron supplementation depending on the severity of the deficiency.
ANAEMIAS CAUSES PREVENTION AND MANAGEMENT.pptxAndrewSilungwe2
Hematopoiesis is the production of blood cells from stem cells, mainly occurring in the bone marrow. It requires iron, vitamin B12, and folic acid. Deficiencies in these can lead to anemia. Iron deficiency anemia is the most common type and appears as hypochromic microcytic anemia. Oral iron supplementation is usually first-line treatment, while parenteral iron may be used for severe or refractory cases. The goals of treatment are to correct the underlying cause, replace iron stores, and alleviate symptoms of anemia.
Anaemia is defined as a reduction in haemoglobin, red blood cells or haematocrit below normal levels. Iron-deficiency anaemia (IDA) affects around 2 billion people worldwide. IDA is prevalent in India, affecting 20% of adult males, 40% of non-pregnant females and children, and 80% of pregnant females. IDA is classified based on its underlying cause such as reduced red blood cell production or increased destruction. Oral iron therapy is usually the first line treatment, while blood transfusions or intravenous iron may be used for more severe cases or those who cannot tolerate oral iron. The diagnosis of IDA relies on a low MCV, MCH and iron studies showing low ferritin and transferrin saturation
There are several types of iron overload disorders, with the most common being β-thalassemia and hereditary hemochromatosis. Iron is absorbed in the duodenum and stored in hepatocytes and macrophages, with levels regulated by the hormone hepcidin. Hereditary hemochromatosis is caused by a mutation in the HFE gene and results in low hepcidin levels and excessive iron absorption. Management of iron overload involves chelation therapy or phlebotomy to remove excess iron from the body.
This document discusses haematinics, which are substances required for blood formation used to treat anaemias. It describes different types of anaemias caused by blood loss, impaired cell formation due to deficiencies in iron, vitamin B12, or folic acid, or increased destruction of red blood cells. It provides details on iron including absorption, transport, storage, requirements, sources, and preparations for both oral and parenteral administration. It also discusses acute iron poisoning treatment and mentions that vitamin B12 and folic acid deficiencies can result in megaloblastic anaemia.
Anemia is defined as a reduction in total circulating red blood cells or hemoglobin. The most common cause of anemia is iron deficiency, which accounts for 83-90% of all anemia cases. Iron deficiency develops in stages, starting with low iron stores and progressing to iron deficiency anemia with low hemoglobin levels and tissue hypoxia. Diagnosis of iron deficiency anemia relies on blood tests showing microcytic hypochromic anemia, low serum iron, ferritin and transferrin saturation, and high total iron binding capacity. Bone marrow examination may also reveal iron deficiency. Early iron deficiency can be detected before anemia occurs using additional tests such as serum transferrin receptor and zinc protoporphyrin.
UAEU - CMHS - Hematology-Oncology Course - MMH 302 - HONC 320. Education material for medical students - It cover basic principles of hematology and oncology, including CAR-T and gene editing. It can be used for study and review. It illustrates main principles of hematology and oncology.
1. Iron overload, also known as hemochromatosis, occurs when the body absorbs more iron than it loses, causing excess iron to accumulate and damage organs. It is commonly caused by a genetic disorder or frequent blood transfusions.
2. Hepcidin regulates iron levels in the body. Iron overload results from low hepcidin leading to increased iron absorption in the gut and spleen.
3. Treatment involves regular phlebotomy to remove excess iron from the body. Phlebotomy can prevent organ damage if started early and allows patients to live normally once iron levels are normalized.
This document discusses iron refractory iron deficiency anemia (IRIDA). It defines key terms like anemia and iron deficiency. It describes normal iron metabolism and the role of transport proteins like DMT1 and ferroportin in intestinal iron absorption. Hepcidin regulates iron transport by binding to ferroportin and inducing its degradation. Mutations in ferroportin can cause iron overload by preventing its binding to hepcidin. The document also discusses rare conditions like atransferrinemia caused by near absence of plasma transferrin.
This document discusses hematopoietic drugs used to treat blood disorders. It describes how hematopoiesis is regulated by growth factors and nutrients, and how deficiencies can cause anemia, thrombocytopenia or neutropenia. It then classifies and describes drugs for treating different types of anemia, such as iron deficiency anemia treated with oral or injectable iron preparations, and megaloblastic anemia treated with vitamin B12 and folic acid supplements. Hematopoietic growth factors like erythropoietin and colony stimulating factors are also outlined for treating related blood conditions.
This document discusses hepcidin, a peptide hormone that plays a central role in regulating iron metabolism. It is predominantly synthesized by hepatocytes and works by binding to ferroportin, a cellular iron exporter, causing its internalization and degradation. This decreases iron absorption from the diet and iron release from cells. The document reviews hepcidin's structure, kinetics, function, and regulation. It also discusses how hepcidin levels are altered in various iron disorders and inflammatory states. Reliable assays have been developed to measure hepcidin levels, showing promise for diagnosing iron disorders, though more research is needed before clinical use.
Iron refractory iron deficiency anemia (IRIDA) is a rare form of inherited anemia caused by mutations in the TMPRSS6 gene. It is characterized by microcytic hypochromic anemia that is refractory to oral iron therapy and has variable response to intravenous iron. The TMPRSS6 gene encodes matriptase-2 which regulates hepcidin levels. Hepcidin is the key hormone that controls iron absorption and recycling. IRIDA results from inappropriately high hepcidin levels due to mutations that prevent matriptase-2 from regulating hepcidin normally. Diagnosis requires genetic testing to identify mutations in TMPRSS6 and treatment involves intravenous iron supplementation.
The document discusses hematinic agents such as iron, folic acid, and vitamin B12 which are used to treat anemia. It covers the pharmacokinetics of iron absorption and transport, indications for hematinic agents including iron deficiency anemia, drug interactions, side effects, and iron toxicity treatment with chelating agents.
The document discusses hematinic agents such as iron, folic acid, and vitamin B12 which are used to treat anemia. It covers the pharmacokinetics of iron absorption and transport, indications for hematinic use including iron deficiency anemia, drug interactions, side effects, and iron toxicity treatment with chelating agents.
The document discusses hematinic agents such as iron, folic acid, and vitamin B12 which are used to treat anemia. It covers the pharmacokinetics of iron absorption and transport, indications for hematinic agents including iron deficiency anemia, drug interactions, side effects, and iron toxicity treatment with chelating agents.
Lung Abscess and Pneumonia (Pathology)Reenaz Shaik
Lung abscess is formed due to necrosis within the pulmonary parenchyma resulting in the formation of cavities.
Pneumonia is due to inflammatory response in lung parenchyma distal to the terminal bronchioles.
Wound Healing is a natural physiological reaction to tissue injury. It involves numerous cell types, cytokines, mediators. Understanding basic wound healing will help in identifying molecular level target genes that can enhance and expedite natural wound healing
Westgard's rules and LJ (Levey Jennings) Charts.Reenaz Shaik
Quality Control is a process used to monitor and evaluate the analytical process that produces patients results. Planning, documenting and agreeing on a set of guidelines ensures quality.
Myeloproliferative disorders describe a group of disorders that result from unchecked, autonomous clonal proliferation of cellular elements of the bone marrow.
JMML is a rare cancer of blood that affects young children. There is a sustained abnormal and excessive production of myeloid progenitors and monocytes.
Chair, Benjamin M. Greenberg, MD, MHS, discusses neuromyelitis optica spectrum disorder in this CME activity titled “Mastering Diagnosis and Navigating the Sea of Targeted Treatments in NMOSD: Practical Guidance on Optimizing Patient Care.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at https://bit.ly/4av12w4. CME credit will be available until June 27, 2025.
Coronary Circulation and Ischemic Heart Disease_AntiCopy.pdfMedicoseAcademics
In this lecture, we delve into the intricate anatomy and physiology of the coronary blood supply, a crucial aspect of cardiac function. We begin by examining the physiological anatomy of the coronary arteries, which lie on the heart's surface and penetrate the cardiac muscle mass to supply essential nutrients. Notably, only the innermost layer of the endocardial surface receives direct nourishment from the blood within the cardiac chambers.
We then explore the specifics of coronary circulation, including the dynamics of blood flow at rest and during strenuous activity. The impact of cardiac muscle compression on coronary blood flow, particularly during systole and diastole, is discussed, highlighting why this phenomenon is more pronounced in the left ventricle than the right.
Regulation of coronary circulation is a complex process influenced by autonomic and local metabolic factors. We discuss the roles of sympathetic and parasympathetic nerves, emphasizing the dominance of local metabolic factors such as hypoxia and adenosine in coronary vasodilation. Concepts like autoregulation, active hyperemia, and reactive hyperemia are explained to illustrate how the heart adjusts blood flow to meet varying oxygen demands.
Ischemic heart disease is a major focus, with an exploration of acute coronary artery occlusion, myocardial infarction, and subsequent physiological changes. The lecture covers the progression from acute occlusion to infarction, the body's compensatory mechanisms, and the potential complications leading to death, such as cardiac failure, pulmonary edema, fibrillation, and cardiac rupture.
We also examine coronary steal syndrome, a condition where increased cardiac activity diverts blood flow away from ischemic areas, exacerbating the condition. The long-term impact of myocardial infarction on cardiac reserve is discussed, showing how the heart's capacity to handle increased workloads is significantly reduced.
Angina pectoris, a common manifestation of ischemic heart disease, is analyzed in terms of its causes, presentation, and referred pain patterns. We identify factors that exacerbate anginal pain and discuss both medical and surgical treatment options.
Finally, the lecture includes a case study to apply theoretical knowledge to a practical scenario, helping students understand the real-world implications of coronary circulation and ischemic heart disease. The role of biochemical factors in cardiac pain and the interpretation of ECG changes in myocardial infarction are also covered.
Causes Of Tooth Loss
PERIODONTAL PROBLEMS ( PERIODONTITIS, GINIGIVITIS)
Systemic Causes Of Tooth Loss
1. Diabetes Mellitus
2. Female Sexual Hormones Condition
3. Hyperpituitarism
4. Hyperthyroidism
5. Primary Hyperparathyroidism
6. Osteoporosis
7. Hypophosphatasia
8. Hypophosphatemia
Causes Of Tooth Loss
CARIES/ TOOTH DECAY
Causes Of Tooth Loss
CAUSES OF TOOTH LOSS
Consequence of tooth loss
Anatomic
Loss of ridge volume both height and width
Bone loss :
mandible > maxilla
Posteriorly > anteriorly
Anatomic consequences
Broader mandibular arch with constricting maxilary arch
Attached gingiva is replaced with less keratinised oral mucosa which is more readily traumatized.
Anatomic consequences
Tipping of the adjacent teeth
Supraeruption of the teeth
Traumatic occlusion
Premature occlusal contact
Anatomic Consequences
Anatomic Consequences
Physiologic consequences
Physiologic Consequences
Decreased lip support
Decreased lower facial height
Physiologic Consequences
Physiologic consequences
Education of Patient
Diagnosis, Treatment Planning, Design, Treatment, Sequencing, and Mouth Preparation
Support for Distal Extension Denture Bases
Establishment and Verification of Occlusal Relations and Tooth Arrangements
Initial Placement Procedures
Periodic Recall
Education of Patient
Informing a patient about a health matter to
secure informed consent.
Patient education should begin at the initial
contact with the patient and should continue throughout treatment.
The dentist and the patient share responsibility for the ultimate success of a removable partial denture.
This educational procedure is especially important when the treatment plan and prognosis are discussed with the patient.
Diagnosis, Treatment Planning, Design, Treatment, Sequencing, and Mouth Preparation
Begin with thorough medical and dental histories.
The complete oral examination must include both clinical and radiographic interpretation of:
caries
the condition of existing restorations
periodontal conditions
responses of teeth (especially abutment teeth) and residual ridges to previous stress
The vitality of remaining teeth
Continued…..
Occlusal plan evaluation
Arch form
Evaluation of Occlusal relationship through mounting the diagnostic cast
The dental cast surveyor is an absolute necessity in which patients are being treated with removable partial dentures.
Mouth preparations, in the appropriate sequence, should be oriented toward the goal of
providing adequate support, stability,
retention, and
a harmonious occlusion for the partial denture.
Support for Distal Extension Denture Bases
A base made to fit the anatomic ridge form does not provide adequate support under occlusal loading.
The base may be made to fit the form of the ridge when under function.
Support for Distal Extension Denture Bases
This provides support
Chair and Presenter, Stephen V. Liu, MD, Benjamin Levy, MD, Jessica J. Lin, MD, and Prof. Solange Peters, MD, PhD, discuss NSCLC in this CME/MOC/NCPD/AAPA/IPCE activity titled “Decoding Biomarker Testing and Targeted Therapy in NSCLC: The Complete Guide for 2024.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/4bBb8fi. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.
Ontotext’s Clinical Trials Eligibility Design Assistant helps with one of the most challenging tasks in study design: selecting the proper patient population.
Hepatocarcinoma today between guidelines and medical therapy. The role of sur...Gian Luca Grazi
Today more than ever, hepatocellular carcinoma therapy is experiencing profound and substantial changes.
The association atezolizumab (ATEZO) plus bevacizumab (BEVA) has demonstrated its effectiveness in the post-operative treatment of patients, improving the results that can be achieved with liver resections. This after the failure of the use of sorafenib in the already historic STORM study.
On the other hand, the prognostic classification of BCLC is now widely questioned. It is now well recognized that the indications for surgery for patients with hepatocellular carcinoma are certainly narrow in BCLC and no longer reflect what is common everyday clinical practice.
Today, the concept of multiparametric therapeutic hierarchy, which makes the management of patients with hepatocellular carcinoma much more flexible and allows the best therapy for the individual patient to be identified based on their clinical characteristics, is gaining more and more importance.
The presentation traces these profound changes that are taking place in recent years and offers a modern vision of the management of patients with hepatocellular carcinoma.
A comparative study on uroculturome antimicrobial susceptibility in apparentl...Bhoj Raj Singh
The uroculturome indicates the profile of culturable microbes inhabiting the urinary tract, and it is often required to do a urine culture to find an effective antimicrobial to treat UTIs. This study targeted to understand the profile of culturable pathogens in the urine of apparently healthy (128) and humans with clinical UTIs (161). In urine samples from UTI cases, microbial counts were 1.2×104 ± 6.02×103 colony-forming units (cfu)/ mL, while in urine samples from apparently healthy humans, the average count was 3.33± 1.34×103 cfu/ mL. In eight samples (six from UTI cases and two from apparently healthy people) of urine, Candida (C. albicans 3, C. catenulata 1, C. krusei 1, C. tropicalis 1, C. parapsiplosis 1, C. gulliermondii 1) and Rhizopus species (1) were detected. Candida krusei was detected only in a single urine sample from a healthy person and C. albicans was detected both in urine of healthy and clinical UTI cases. Fungal strains were always detected with one or more types of bacteria. Gram-positive bacteria were more commonly (OR, 1.98; CI99, 1.01-3.87) detected in urine samples of apparently healthy humans, and Gram -ve bacteria (OR, 2.74; CI99, 1.44-5.23) in urines of UTI cases. From urine samples of 161 UTI cases, a total of 90 different types of microbes were detected and, 73 samples had only a single type of bacteria. In contrast, 49, 29, 3, 4, 1, and 2 samples had 2, 3, 4, 5, 6 and 7 types of bacteria, respectively. The most common bacteria detected in urine of UTI cases was Escherichia coli detected in 52 samples, in 20 cases as the single type of bacteria, other 34 types of bacteria were detected in pure form in 53 cases. From 128 urine samples of apparently healthy people, 88 types of microbes were detected either singly or in association with others, from 64 urine samples only a single type of bacteria was detected while 34, 13, 3, 11, 2 and 1 samples yielded 2, 3, 4, 5, 6 and seven types of microbes, respectively. In the urine of apparently healthy humans too, E. coli was the most common bacteria, detected in pure culture from 10 samples followed by Staphylococcus haemolyticus (9), S. intermedius (5), and S. aureus (5), and similar types of bacteria also dominated in cases of mixed occurrence, E. coli was detected in 26, S. aureus in 22 and S. haemolyticus in 19 urine samples, respectively. Gram +ve bacteria isolated from urine samples' irrespective of health status were more often (p, <0.01) resistant than Gram -ve bacteria to ajowan oil, holy basil oil, cinnamaldehyde, and cinnamon oil, but more susceptible to sandalwood oil (p, <0.01). However, for antibiotics, Gram +ve were more often susceptible than Gram -ve bacteria to cephalosporins, doxycycline, and nitrofurantoin. The study concludes that to understand the role of good and bad bacteria in the urinary tract microbiome more targeted studies are needed to discern the isolates at the pathotype level.
Case presentation of a 14-year-old female presenting as unilateral breast enlargement and found to have a giant breast lipoma. The tumour was successfully excised with the result that the presumed unilateral breast enlargement reverting back to normal. A review of management including a photo of the removed Giant Lipoma is presented.
Why Does Seminal Vesiculitis Causes Jelly-like Sperm.pptxAmandaChou9
Seminal vesiculitis can cause jelly-like sperm. Fortunately, herbal medicine Diuretic and Anti-inflammatory Pill can eliminate symptoms and cure the disease.
Hemodialysis: Chapter 8, Complications During Hemodialysis, Part 2 - Dr.GawadNephroTube - Dr.Gawad
- Video recording of this lecture in English language: https://youtu.be/FHV_jNJUt3Y
- Video recording of this lecture in Arabic language: https://youtu.be/D5kYfTMFA8E
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
2. Anemia
1.6 Billion
people affected
globally with
anemia
Most common:
Iron Deficiency
Anemia
Key Regulator
in Iron
Metabolism:
Hepcidin
Iron deficiency anemia
Iron refractory anemia
Iron overload
Anemia of Chronic
Disease
Anemia in kidney
disease
Hepcidin acts as a
Moderator in:
3. Iron
• A typical human adult has about 3-5 grams of total body iron.
60% of iron is found in circulating haemoglobin
10% in myoglobin in muscles
20% is stored in liver cells (hepatocytes and Kupffer cells) as ferritin
Rest is divided between enzymes such as cytochromes, peroxidases,
catalase and others.
• To replenish the daily loss of 1-2 mg of iron from mucosal cell sloughing,
sweat and urine excretion, duodenal enterocytes must absorb an equal
amount of iron.
4. Iron Homeostasis
Duodenal
enterocytes
Absorb iron
Erythroid
precursors
Use Iron
Hepatocytes
and tissue
macrophages
Store Iron
Splenic
macrophages
Recycle Iron
Iron concentrations in our body
are tightly regulated both at
cellular level and systemic level.
Crucial element in maintenance of
Iron homeostasis is effective
communication between
absorption, storage, usage and
recycling of Iron.
5. Hepcidin
• Hepcidin is a peptide hormone synthesised in hepatocytes. It is
composed of 25 amino acids and includes 4 disulfide bonds which binds
with ferroportin.
• Normal range for plasma hepcidin is in range of 1 to 55 ng/ml.
Decreases Iron Absorption
Increases Iron Absorption
6. Iron Absorption and Hepcidin
Iron absorption takes place at the
apical surface of duodenal
enterocytes.
Non-haem iron is released from
food as Fe3+ (ferric iron) and
reduced to Fe2+ (ferrous iron) by
duodenal cytochrome b (DCYTB).
Iron is then transported across the
brush-border membrane by the
divalent metal transporter DMT1.
Iron is transported across the
serosal membrane by ferroportin-1.
7. Potential of Hepcidin as a marker
• Hepcidin can help in diagnosis of Iron deficiency anemia even before routine
haematological parameters and iron profile diagnose anemia.
• Hepcidin helps in differentiating Iron deficiency Anemia and Anemia of Chronic Disease
• Few studies have shown that hepcidin antibodies, BMP agonists or antagonists, cytokine
receptor antibodies can modify hepcidin expression and reverse iron abnormalities in vivo.
• Hepcidin has emerged as the potential marker as it has a known
mechanism of action
good stability
rapid response to iron stores, inflammatory stimuli and bacterial infections
8. Regulation of Hepcidin
Physiological Induction of Hepcidin: Bone morphogenetic protein
(BMP) along with hemochromatosis protein (HFE), transferrin receptor
2 (TFR2), hemojuvelin (HJV), Metallothionein (MT2) and a specific iron-
related bone morphogenetic protein, BMP6 activates SMAD signalling
pathway. This causes hepcidin transcription.
Pathological hepcidin induction: During inflammation or infection,
interleukin-6 (IL-6) increase hepcidin production. Activation of JAK-
STAT3 pathway by IL6 promotes hepcidin production.
10. Regulation of Hepcidin
• Physiological hepcidin suppression: When there is an increased demand for
iron during anemia and hypoxia, hepcidin is supressed, independent of the
amount of iron stores present. This is indirectly mediated by the hormone
erythropoietin (EPO) and erythroferrone.
• Pathologic hepcidin suppression: Occurs in the iron-loading anemia. Hepcidin
transcription is suppressed by exuberant but ineffective erythropoiesis.
Hepcidin is also supressed by the cytokines GDF-15 (Growth Differentiating
Factor), TWSG1 (Twisted granulation BMP signalling modulator), Hepatocyte
growth factor (HGF), Epidermal growth factor (EGF).
11. Correlation of Hepcidin with other anemia markers
Hepcidin Condition Biochemical markers Haematological
markers
Low Iron Deficiency Iron, Ferritin, Tfs
TIBC
Hb , MCV, MCH
RDW
Low Ineffective
erythropoiesis
Iron, Ferritin, Tfs Hb
N RDW
Low Iron Overload Iron, Ferritin, Tfs Hb, MCV, MCH
High Anemia of Chronic
Disease
Iron, Tfs, TIBC
Ferritin
Hb, MCV, MCH
N RDW
12. Physiological Process in Different Anaemia's:
Type of Anemia Hepcidin
level
Physiological Process
Iron Deficiency Anemia Low Suppression by Erythropoietin
Iron Refractory Anemia High Mutation of TMPRSS6 (Suppressor Matriptase)
Iron Overload Low Suppression due to increased erythropoietic
activities which increases Erythroferrone
Ineffective Erythropoiesis Low Suppression by Cytokines GDF15 and TWSG1
Anemia of Chronic Disease High Induction by Interleukin 6
Anemia in Kidney Disease High Decreased hepcidin clearance and lack of
erythropoietin
Beta Thalassemia (pre-transfusion) Low Suppression by Cytokine GDF15
Beta Thalassemia (post-transfusion) High Due to suppression of erythropoietin
Megaloblastic Anemia Low Decreased nucleotide production causes
ineffective erythropoiesis.
Leukaemia and Lymphoma High Induction by BMP6 and IL6